172 related articles for article (PubMed ID: 37207210)
1. Multi-omics analysis of Siglec family genes in cutaneous melanoma.
Li K; Xu N; Guo S
Front Immunol; 2023; 14():1036019. PubMed ID: 37207210
[TBL] [Abstract][Full Text] [Related]
2. Gene conversions are frequent but not under positive selection in the Siglec gene families of primates.
Zid M; Drouin G
Genome; 2014 Jun; 57(6):317-25. PubMed ID: 25166301
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of a siglec-based and aging-related 9-gene signature for predicting prognosis in acute myeloid leukemia patients.
Shi H; Gao L; Zhang W; Jiang M
BMC Bioinformatics; 2022 Jul; 23(1):284. PubMed ID: 35854240
[TBL] [Abstract][Full Text] [Related]
4. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.
Angata T; Varki A
J Biol Chem; 2000 Jul; 275(29):22127-35. PubMed ID: 10801860
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
6. Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters.
Angata T; Hingorani R; Varki NM; Varki A
J Biol Chem; 2001 Nov; 276(48):45128-36. PubMed ID: 11579105
[TBL] [Abstract][Full Text] [Related]
7. Siglecs in Brain Function and Neurological Disorders.
Siddiqui SS; Matar R; Merheb M; Hodeify R; Vazhappilly CG; Marton J; Shamsuddin SA; Al Zouabi H
Cells; 2019 Sep; 8(10):. PubMed ID: 31546700
[TBL] [Abstract][Full Text] [Related]
8. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins.
Bornhöfft KF; Goldammer T; Rebl A; Galuska SP
Dev Comp Immunol; 2018 Sep; 86():219-231. PubMed ID: 29751010
[TBL] [Abstract][Full Text] [Related]
9. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus.
Ren X; Ji Y; Jiang X; Qi X
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30355653
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
Ikehara Y; Ikehara SK; Paulson JC
J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
[TBL] [Abstract][Full Text] [Related]
12. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.
Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A
J Biol Chem; 2014 Nov; 289(48):33481-91. PubMed ID: 25320078
[TBL] [Abstract][Full Text] [Related]
13. High-affinity ligands of Siglec receptors and their therapeutic potentials.
Magesh S; Ando H; Tsubata T; Ishida H; Kiso M
Curr Med Chem; 2011; 18(23):3537-50. PubMed ID: 21756229
[TBL] [Abstract][Full Text] [Related]
14. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands.
Rodrigues E; Jung J; Park H; Loo C; Soukhtehzari S; Kitova EN; Mozaneh F; Daskhan G; Schmidt EN; Aghanya V; Sarkar S; Streith L; St Laurent CD; Nguyen L; Julien JP; West LJ; Williams KC; Klassen JS; Macauley MS
Nat Commun; 2020 Oct; 11(1):5091. PubMed ID: 33037195
[TBL] [Abstract][Full Text] [Related]
15. Identification of therapeutic targets and prognostic biomarkers in the Siglec family of genes in tumor immune microenvironment of sarcoma.
Qi L; Jiang K; Zhao FF; Ren P; Wang L
Sci Rep; 2024 Jan; 14(1):577. PubMed ID: 38182638
[TBL] [Abstract][Full Text] [Related]
16. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
17. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
[TBL] [Abstract][Full Text] [Related]
18. Ganglioside binding pattern of CD33-related siglecs.
Rapoport E; Mikhalyov I; Zhang J; Crocker P; Bovin N
Bioorg Med Chem Lett; 2003 Feb; 13(4):675-8. PubMed ID: 12639556
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Siglec-8 expression predicts adverse prognosis in patients with clear cell renal cell carcinoma.
Ou C; Liu L; Wang J; Dai S; Qu Y; Xiong Y; Xi W; Xu J; Guo J
Urol Oncol; 2017 Oct; 35(10):607.e1-607.e8. PubMed ID: 28619634
[TBL] [Abstract][Full Text] [Related]
20. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
Mitic N; Milutinovic B; Jankovic M
Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]